Life Sciences

Life sciences companies operate in an environment where intellectual property, regulatory requirements, and commercial timelines are closely interconnected. Developing new therapies, diagnostics, medical technologies, and related healthcare innovations often involves significant investment and lengthy development cycles, making it essential to secure IP rights that support both early-stage milestones and long-term value. Early decisions can influence freedom-to-operate, licensing opportunities, investment planning, regulatory strategy, market positioning, and the scope of exclusivity available once a product reaches market.

Leason Ellis advises academic institutions, startups, solopreneurs, and established companies on building and protecting intellectual property in biotechnology, pharmaceuticals, diagnostics, medical technologies, and related areas, including biologics, cell and gene therapies, vaccines, and emerging healthcare innovations. We handle patent prosecution, portfolio development, opinions, due diligence, and strategic contentious matters, including post-grant proceedings, international oppositions, expert witness work, and litigation support. Our approach is strategic and measured, with a focus on efficient, business-aligned guidance.

We help clients identify which innovations are worth protecting and structure portfolios around development timelines, commercial priorities, funding realities, and intended markets. Our counsel often extends beyond filing strategy to broader questions of licensing, foreign filing, manufacturing, enforcement, and the relationship between patent protection and regulatory exclusivity. This allows clients to make informed decisions about how to position, use, and protect intellectual property at different stages of development and commercialization.

Working closely with scientific, legal, and business teams, we integrate intellectual property strategy with regulatory pathways, investment considerations, and market-entry plans. Our interdisciplinary team brings together diverse technical backgrounds to support complex innovations, including diagnostics, AI-driven healthcare technologies, and other developments where biological, computational, engineering, and medical issues intersect.

Clients work directly with senior lawyers in collaborative teams that provide experienced guidance without unnecessary layers of management. Our approach emphasizes clarity, practical judgment, and a strong understanding of the broader context in which life sciences companies operate, including development timelines, regulatory approval pathways, exclusivity periods, target markets, and financing considerations. By asking deeper questions about where an innovation is going, how it will be used, and what it needs to support strategically, we help clients align intellectual property decisions with the realities of development, approval, and market entry.